Nextage Therapeutics Ltd (TA:NXTG) — Market Cap & Net Worth
Market Cap & Net Worth: Nextage Therapeutics Ltd (NXTG)
Nextage Therapeutics Ltd (TA:NXTG) has a market capitalization of $5.79 Million (ILA2.16 Billion) as of June 22, 2026. Listed on the TA stock exchange, this Israel-based company holds position #28282 globally and #410 in its home market, demonstrating a -17.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nextage Therapeutics Ltd's stock price ILA64.10 by its total outstanding shares 33697211 (33.70 Million). Review Nextage Therapeutics Ltd (NXTG) financial obligations to assess the company's total debt and financial obligations.
Nextage Therapeutics Ltd Market Cap History: 2015 to 2026
Nextage Therapeutics Ltd's market capitalization history from 2015 to 2026. Data shows growth from $437.25 Million to $5.79 Million (28.33% CAGR).
Nextage Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nextage Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
17.17x
Nextage Therapeutics Ltd's market cap is 17.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $114.01 Million | $405.00K | -$5.73 Million | 281.51x | N/A |
| 2018 | $72.81 Million | $383.00K | -$8.73 Million | 190.12x | N/A |
| 2019 | $77.87 Million | $297.00K | -$2.09 Million | 262.20x | N/A |
| 2020 | $27.89 Million | $191.00K | -$15.97 Million | 146.01x | N/A |
| 2021 | $19.96 Million | $91.00K | -$7.73 Million | 219.30x | N/A |
| 2023 | $3.03 Million | $876.00K | -$3.88 Million | 3.45x | N/A |
| 2024 | $7.09 Million | $413.00K | -$3.28 Million | 17.17x | N/A |
Competitor Companies of NXTG by Market Capitalization
Companies near Nextage Therapeutics Ltd in the global market cap rankings as of June 22, 2026.
Key companies related to Nextage Therapeutics Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
Nextage Therapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Nextage Therapeutics Ltd's market cap moved from $437.25 Million to $ 5.79 Million, with a yearly change of 28.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA5.79 Million | -17.72% |
| 2025 | ILA7.04 Million | -0.76% |
| 2024 | ILA7.09 Million | +134.33% |
| 2023 | ILA3.03 Million | -42.44% |
| 2022 | ILA5.26 Million | -73.65% |
| 2021 | ILA19.96 Million | -28.44% |
| 2020 | ILA27.89 Million | -64.19% |
| 2019 | ILA77.87 Million | +6.95% |
| 2018 | ILA72.81 Million | -36.13% |
| 2017 | ILA114.01 Million | -38.26% |
| 2016 | ILA184.66 Million | -57.77% |
| 2015 | ILA437.25 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Nextage Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.79 Million USD |
| MoneyControl | $5.79 Million USD |
| MarketWatch | $5.79 Million USD |
| marketcap.company | $5.79 Million USD |
| Reuters | $5.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nextage Therapeutics Ltd
Nextage Therapeutics Ltd, a pharmaceutical company, develops cannabinoid-based products. The company was formerly known as Nextage Cannabis Innovation Ltd. and changed its name to Nextage Therapeutics Ltd in August 2020. The company was incorporated in 1982 and is based in Ness Ziona, Israel.